SUT BEZI SARATONIDA QO‘LLANILADIGAN AYRIM DORI VOSITALARI VA XALQ TABOBATINING IMKONIYATLARI
DOI:
https://doi.org/10.55475/jcgtm/vol5.iss5.2026.782Kalit so'zlar:
sut bezi saratoni, kimyoterapiya, nojo‘ya ta’sirlar, xalq tabobatiAnnotatsiya
Maqolada sut bezi saratonini davolashda qo‘llaniladigan asosiy sintetik dori vositalarining foydali tomonlari va asoratlari yoritilgan. Shuningdek, xalq tabobati va integrativ usullarning standart davolash bilan birga qo‘llanishi, ularning ilmiy asoslangan imkoniyatlari tahlil qilingan.
References
Bray F., Laversanne M., Sung H. va boshq. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: A Cancer Journal for Clinicians. – 2024. – Vol. 74, №3. – P. 229–263. DOI: https://doi.org/10.3322/caac.21834
O‘zbekistonda onkologik yordam modernizatsiya qilinmoqda // Anhor.uz. – URL: https://anhor.uz/uzl/news/ozbekistonda-onkologik-yordam-modernizatsiya-qilinmoqda/
Loibl S., André F., Bachelot T. va boshq. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Annals of Oncology. – 2024. – Vol. 35, №2. – P. 159–182. DOI: https://doi.org/10.1016/j.annonc.2023.11.016
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials // Lancet. – 2012. – Vol. 379, №9814. – P. 432–444. DOI: https://doi.org/10.1016/S0140-6736(11)61625-5
Lyon A.R., López-Fernández T., Couch L.S. va boshq. 2022 ESC Guidelines on cardio-oncology // European Heart Journal. – 2022. – Vol. 43, №41. – P. 4229–4361.
Loprinzi C.L., Lacchetti C., Bleeker J. va boshq. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update // Journal of Clinical Oncology. – 2020. – Vol. 38, №28. – P. 3325–3348. DOI: https://doi.org/10.1200/JCO.20.01399
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials // Lancet. – 2015. – Vol. 386, №10001. – P. 1341–1352. DOI: https://doi.org/10.1016/S0140-6736(15)61074-1
Modi S., Jacot W., Yamashita T. va boshq. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer // New England Journal of Medicine. – 2022. – Vol. 387, №1. – P. 9–20. DOI: https://doi.org/10.1056/NEJMc2210368
Schmid P., Cortes J., Dent R. va boshq. Overall survival with pembrolizumab in early-stage triple-negative breast cancer // New England Journal of Medicine. – 2024. – Vol. 391, №21. – P. 1981–1991. DOI: https://doi.org/10.1056/NEJMe2411492
Acupuncture reduces joint pain due to breast cancer treatment // NewYork-Presbyterian. – 10.07.2018. – URL: https://www.nyp.org/news/acupuncture-reduces-joint-pain-due-to-breast-cancer-treatment
Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia // Journal of the American Chemical Society. – 1971. – Vol. 93, №9. – P. 2325–2327. DOI: https://doi.org/10.1021/ja00738a045
Newman D.J., Cragg G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019 // Journal of Natural Products. – 2020. – Vol. 83, №3. – P. 770–803. DOI: https://doi.org/10.1021/acs.jnatprod.9b01285
И.Р.Асқаров. Табобат қомуси. Мумтоз сўз. Тошкент – 2019. – 1590 б.
И.Р.Асқаров. Сирли табобат. – Т: Фан ва технологиялар нашриёт-матбаа уйи. 2021. – 1084 б.
Guideline addresses use of integrative therapies for cancer-related pain management // Healio. – 30.11.2022. – URL: https://cm.healio.com/news/hematology-oncology/20221130/guideline-addresses-use-of-integrative-therapies-for-cancerrelated-pain-management
Greenlee H., DuPont-Reyes M.J., Balneaves L.G. va boshq. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment // CA: A Cancer Journal for Clinicians. – 2017. – Vol. 67, №3. – P. 194–232. DOI: https://doi.org/10.3322/caac.21397
Lyman G.H., Greenlee H., Bohlke K. va boshq. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline // Journal of Clinical Oncology. – 2018. – Vol. 36, №25. – P. 2647–2655. doi:10.1200/JCO.2018.79.2721 DOI: https://doi.org/10.1200/JCO.2018.79.2721
SIO guideline on the use of integrative therapies for breast cancer // Medical Dialogues. – 20.06.2018. – URL: https://speciality.medicaldialogues.in/sio-guideline-on-the-use-of-integrative-therapies-for-breast-cancer
Integrative Therapies During and After Breast Cancer Treatment: Key Recommendations // Guideline Central. – URL: https://guidelinecentral.com/guideline/39773
Hershman D.L., Unger J.M., Greenlee H. va boshq. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial // JAMA. – 2018. – Vol. 320, №2. – P. 167–176. doi:10.1001/jama.2018.8907 DOI: https://doi.org/10.1001/jama.2018.8907
Downloads
Nashr etilgan
How to Cite
License
Copyright (c) 2026 Ибрагим Рахманович Аскаров, Санжарбек Тойирович Сайдуллаев, Миржалол Мукимжон угли Муминджонов

This work is licensed under a Creative Commons Attribution 4.0 International License.
Mazkur jurnalda e'lon qilingan maqolalarning mualliflik huquqi, undagi ilmiy yangiliklar, tadqiqot natijalariga javobgarlik maqola mualliflariga tegishli hisoblanadi. Mazkur mualliflik huquqi "Creative Commons "Attribution" 4.0" xalqaro qoidaga asosan belgilanadi.